siRNA-Encapsulated Poly (Lactic--Glycolic Acid) Nanoparticles Diminish Neuropathic Pain by Inhibiting Microglial Activation.

Activation of nuclear factor-kappa B (NF-κB) in microglia plays a decisive role in the progress of neuropathic pain, and the inhibitor of kappa B (IκB) is a protein that blocks the activation of NF-κB and is degraded by the inhibitor of NF-κB kinase subunit beta (IKBKB). The role of is to break down IκB, which blocks the activity of NF-kB. Therefore, it prevents the activity of NK-kB. This study investigated whether neuropathic pain can be reduced in spinal nerve ligation (SNL) rats by reducing the activity of microglia by delivering small interfering RNA (siRNA)-encapsulated poly (lactic--glycolic acid) (PLGA) nanoparticles. PLGA nanoparticles, as a carrier for the delivery of genes silencer, were used because they have shown potential to enhance microglial targeting. SNL rats were injected with siRNA-encapsulated PLGA nanoparticles intrathecally for behavioral tests on pain response. siRNA was delivered for suppressing the expression of . In rats injected with siRNA-encapsulated PLGA nanoparticles, allodynia caused by mechanical stimulation was reduced, and the secretion of pro-inflammatory mediators due to NF-κB was reduced. Delivering siRNA through PLGA nanoparticles can effectively control the inflammatory response and is worth studying as a treatment for neuropathic pain.